Navigation Links
Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
Date:5/31/2008

se for 90 days or more or a complete or partial response. The preliminary median Progression Free Survival was 91 days, or 13 weeks, at the 48 mg/m(2) dose; twenty-three patients treated at this dose remained on study as of May 12, 2008.

All patients enrolled in the trial have previously failed treatment with platinum-containing regimens, and 26 patients have also failed prior treatment with doxorubicin HCl liposome injection (Doxil(R)). Both platinum-resistant and Doxil-resistant patients in the Phase 2 clinical trial have responded to voreloxin therapy.

In March, based on the indications of clinical activity and the acceptable tolerability profile demonstrated in this Phase 2 clinical trial, Sunesis increased the dose of voreloxin in this trial to 60 mg/m(2) once every 28 days. Thirty-four patients have been enrolled at the 60 mg/m(2) dose level. To date, with an initial eight patients evaluable for efficacy response, one patient has achieved a partial response.

Voreloxin has been well-tolerated in the platinum-resistant ovarian cancer population. With 65 patients evaluable for safety at the 48 mg/m(2) dose and 20 patients evaluable for safety at the 60 mg/m(2) dose, low rates of febrile neutropenia (<10%) or other Grade 3-4 adverse events (fatigue (12%), vomiting (5%) and infections (5% )) have been observed. Based on voreloxin's safety profile, Sunesis recently announced that the protocol for the ongoing Phase 2 clinical trial was amended to increase the dose by 25 percent to 75 mg/m(2) given once every 28 days. Sunesis expects to enroll approximately 30 patients at this new dose level by the end of this year.

"Voreloxin has demonstrated promising clinical activity and tolerability among platinum-resistant ovarian cancer patients and we are focused on advancing this compound in this indication toward late-stage trials," said Daniel Swisher, Sunesis' Chief Executive Officer. "We are pleased by the rapid progress of enrollment of vorelo
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
3. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
4. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
7. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
10. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... , July 10, 2014   LabStyle ... Management Solution, today announced the appointment of Professor ... member of its Board of Directors. ... and business experience to LabStyle as an entrepreneur, ... legal and corporate governance expert. He currently serves ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Feb. 22, 2011 Reportlinker.com announces that a ... catalogue: Global Pharmaceutical Contract Manufacturing ... This report analyzes the worldwide markets for ... following Dosage Forms: Injectables (Injections, Vials, and IV ...
... MedTrust Online (MedTrust) and Avantra Biosciences (Avantra) ... in the earliest stages of molecular diagnostic assay ... system. The two companies will ... care professionals with early access to the latest ...
Cached Medicine Technology:Reportlinker Adds Global Pharmaceutical Contract Manufacturing Industry 2Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care 2Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care 3
(Date:7/13/2014)... 13, 2014 The North American water storage ... 2013 to $5,450 million by 2018, at a CAGR of ... is expanding at a rapid pace in North America. The ... laws on water & wastewater storage and collection, and the ... market is expanding at a healthy rate in Canada, and ...
(Date:7/13/2014)... Advanced boilers are preferred over conventional boilers because ... produce high-capacity power, emit fewer pollutants, and provide ... climate change concerns, many countries have implemented strict ... pollutants coming from fossilfuel-based power plants.North America had ... market., The global power rental market is witnessing ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
(Date:7/13/2014)... The Pearland, Texas location of The Little ... four months to 12 years of age that offers everything ... parties and Summer Camps, is now under new ownership. , ... after spending over six years at The Little Gym ... , Berry has over ten years of experience working ...
(Date:7/13/2014)... 2014 Recently, 2014QuinceaneraDresses.com, the distinguished ... its new range of gorgeous Quinceanera dresses ... demand for elegant Quinceanera outfits is huge. Therefore, ... All the company’s newly released dresses are made ... all elegant and vivid. , It is ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2
... Simulator, from Electronic Sports, leads the next generation of exergaming fitness ... fun. , ... Salt Lake City, UT (PRWEB) December ... Dogfight, a full featured flight simulator interfaced with a high-end exercise ...
... PORTAGE, Ind., Dec. 16 MonoSol Rx, the ... company specializing in dissolving thin film pharmaceutical products, ... an agreement for thin film pharmaceutical products with ... a multinational pharmaceutical group focused on developing, manufacturing ...
... second Indiana Planned Parenthood clinic shows an emerging pattern of ... report the statutory rape of young girls. The new footage ... Project," a series of investigations documenting how secret abortions keep ... , In the video, shot undercover ...
... England and SAN FRANCISCO, Dec. 16 Enigma Diagnostics ... today that it has signed a term sheet for ... (RMS). , , The ... or licensed by RMS and its affiliates to practice ...
... BOTHELL, Wash., Dec. 16 SCOLR Pharma, Inc. (NYSE Alternext: DDD) ... Officer of the Company and as a member of its Board ... , Michael N. Taglich, Chairman of the Board of ... SCOLR,s entire organization, I would like to thank Dan for his ...
... Healthways executive brings 14-plus years of health industry expertise ... MINNEAPOLIS, Dec. 16 HealthFitness (NYSE Alternext ... as senior vice president of business and corporate development. ... services for on-site and dispersed employee populations. , ...
Cached Medicine News:Health News:Electronic Sports Launches Dogfight Fitness Flight Simulator: The Next Generation of Exergaming 2Health News:Electronic Sports Launches Dogfight Fitness Flight Simulator: The Next Generation of Exergaming 3Health News:MonoSol Rx Enters Agreement with Hikma Pharmaceuticals PLC for Thin Film Pharmaceutical Products in the Middle East 2Health News:MonoSol Rx Enters Agreement with Hikma Pharmaceuticals PLC for Thin Film Pharmaceutical Products in the Middle East 3Health News:Abuse Pattern Develops as Second Indiana Planned Parenthood Covers Up Statutory Rape of 13-Year-Old 2Health News:Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc. 2Health News:SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds 2Health News:New SVP of Business and Corporate Development Joins HealthFitness 2
B-Hemoglobin test system provide quick, simple and reliable quantitative hemoglobin results. It has unbreakable, disposable cuvette which collect the exact amount of blood and mixes the sample with t...
... Variant hemoglobin testing system ... testing for diabetes monitoring, ... testing, hemoglobinopathy screening and ... single test. It has ...
AcT 5diff OV enables low-volume labs to advance to 5-part differential analysis at an affordable price. This analyzer delivers accurate test results and a user-friendly software interface in a compac...
... LH 755 simplifies and automates ... expert automation and advanced technologies ... reliable, accurate results every time. ... slide quality with its slide-on-slide ...
Medicine Products: